Investor Relations

A FULLY INTEGRATED INNOVATIVE ONCOLOGY COMPANY WITH A ROBUST PIPELINE AND PROVEN COMMERCIAL CAPABILITIES IN ONCOLOGY.

Coherus is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), growing revenues and a promising pipeline that includes two mid-stage clinical candidates targeting liver, head & neck, prostate, colon and gastric cancer. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners’, driving sales multiples and synergies from proprietary combinations. Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colon cancer and gastric cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with hepatocellular carcinoma.

Coherus is headquartered in the heart of California’s Silicon Valley and comprised of a team of industry veterans with decades of experience in developing and commercializing Oncology therapies.